Promising prostate cancer treatment trial halted early
NCT ID NCT04876651
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 3 study tested a radioactive antibody called 177Lu-DOTA-rosopatamab combined with standard care for men with metastatic castration-resistant prostate cancer that had progressed after hormone therapy. The goal was to see if the combination slowed cancer growth or improved survival. However, the trial was terminated early and only enrolled 16 participants, so the findings are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
177Lu-DOTA-rosopatamab (a radioactive antibody targeting prostate cancer cells)
What this could lead to
If successful, this combination could offer a new treatment option for men with advanced prostate cancer that has stopped responding to hormone therapy.
What could go wrong
The trial was terminated early with only 16 participants, so results are very limited. It is unclear if the treatment is safe or effective, and it may not work for all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
'GenesisCare Murdoch'
Murdoch, Western Australia, 6150, Australia
-
Auckland City Hospital
Auckland, 1023, New Zealand
-
Austin Health
Melbourne, Victoria, 3083, Australia
-
Monash Health
Clayton, Victoria, 3168, Australia
-
Princess Alexandra Hospital
Woolloongabba, Queensland, 4102, Australia
-
Westmead Hospital
Westmead, New South Wales, 2145, Australia